top of page

Free Biopharma Daily Stock Updates - 06/23/21

$XBI $134.31 +0.50%


Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!


Covid Updates

$TLSA +5.4% Tiziana Life Sci PLC - P2 Trial with foralumab on Severe COVID19 Patients source

Pipeline Updates

$AZN +0.0% Orpathys approved in China for patients with lung cancer and MET gene alterations source

$KRTX -4.0% Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers source

$VBIV +0.0% Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021 source

$CLVS +5.0% Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open For Enrollment source

$GMDA +4.50% Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant source

$EDIT +4.0% Editas Medicine Announces Enrollment Of The First Pediatric Cohort In The BRILLIANCE Clinical Trial Of EDIT-101 For The Treatment Of LCA10 Following IDMC Endorsement source

$CYTK +0.1% Cytokinetics Announces Three Presentations To Occur At The European Society Of Cardiology Heart Failure 2021 Congress source

$ARWR -1.0% Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress source

$JNCE +0.0% Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day source

$LPCN +1.0% Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event source

$ASMB +0.25% Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress™ EASL 2021 source

$COCP +2.3% Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter source

$PTCT +0.35% Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy source

$SCYX +5.4% SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets) source

$XBIT +1.0% XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer source

$MDNA -6.8% Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11 source

$MIRM +1.5% Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021 source

$DRRX -0.6% DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic Impairment at the International Liver Conference 2021 (EASL) source

$YMAB +0.6% Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma source

$VALN -0.4% Valneva Announces Successful Outcome of its AGM source

$RUBY +0.2% Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors source

$AGTC +0.7% AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials source

$RCUS +3.0% Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study source

$GNFT -1.0% GENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes Association source

Financial Updates

$LMNL -0.50% Liminal BioSciences Announces Signature of a Share Purchase Agreement for Sale of Remaining Plasma-derived Business with Kedrion source


Posted by JM



bottom of page